Drugs / GB18
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07519564 | Jun 2026 → Sep 2027 expected | hypoproteinemia, hypercatabolic | Kexing Biopharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07237464 | Oct 2025 → Jan 2026 overdue | — | Shenzhen Kexing Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07519564 ↗ |
| Modality | Monoclonal antibody | “As a humanized GDF15 monoclonal antibody, GB18 is expected to improve anorexia and weight loss caused by metabolic disorders driven by overactivation of the GDF15-GFRAL-RET...” NCT07519564 ↗ |
| Route | Subcutaneous | “single subcutaneous (SC) administered dose” NCT07237464 ↗ |
| Target | GDF15 | “As a humanized GDF15 monoclonal antibody, GB18 is expected to improve anorexia and weight loss caused by metabolic disorders driven by overactivation of the GDF15-GFRAL-RET...” NCT07519564 ↗ |